Genetic variation in statin intolerance and a possible protective role for UGT1A1

Maria Alice V. Willrich, Erin J. Kaleta, Sandra C. Bryant, Grant M. Spears, Laura J. Train, Sandra E. Peterson, Vanda A Lennon, Stephen L. Kopecky, Linnea M. Baudhuin

Research output: Contribution to journalArticle

Abstract

The etiology of statin intolerance is hypothesized to be due to genetic variants that impact statin disposition and clearance. We sought to determine whether genetic variants were associated to statin intolerance. The studied cohort consisted of hyperlipidemic participants (n = 90) clinically diagnosed with statin intolerance by a cardiologist and matched controls without statin intolerance. Creatine kinase activity, lipid profiles and genetic analyses were performed on genes involved in statin metabolism and included UGT1A1 and UGT1A3 sequencing and targeted analyses of CYP3A4∗22, CYP3A5∗3, SLCO1B1∗5 and ∗1b, ABCB1 c.3435C>T, ABCG2 c.421C>A and GATM rs9806699. Although lipids were higher in cases, genetic variant minor allele frequencies were similar between cases and controls, except for UGT1A1∗28, which was less prevalent in cases than controls.

Original languageEnglish (US)
Pages (from-to)83-94
Number of pages12
JournalPharmacogenomics
Volume19
Issue number2
DOIs
StatePublished - Jan 1 2018

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipids
Creatine Kinase
Gene Frequency
Genes

Keywords

  • ABC transporters
  • CYP3A
  • GATM
  • genetic variants
  • myotoxicity
  • precision medicine
  • SLC
  • statin intolerance
  • statins
  • transporters
  • UGT

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Willrich, M. A. V., Kaleta, E. J., Bryant, S. C., Spears, G. M., Train, L. J., Peterson, S. E., ... Baudhuin, L. M. (2018). Genetic variation in statin intolerance and a possible protective role for UGT1A1. Pharmacogenomics, 19(2), 83-94. https://doi.org/10.2217/pgs-2017-0146

Genetic variation in statin intolerance and a possible protective role for UGT1A1. / Willrich, Maria Alice V.; Kaleta, Erin J.; Bryant, Sandra C.; Spears, Grant M.; Train, Laura J.; Peterson, Sandra E.; Lennon, Vanda A; Kopecky, Stephen L.; Baudhuin, Linnea M.

In: Pharmacogenomics, Vol. 19, No. 2, 01.01.2018, p. 83-94.

Research output: Contribution to journalArticle

Willrich, MAV, Kaleta, EJ, Bryant, SC, Spears, GM, Train, LJ, Peterson, SE, Lennon, VA, Kopecky, SL & Baudhuin, LM 2018, 'Genetic variation in statin intolerance and a possible protective role for UGT1A1', Pharmacogenomics, vol. 19, no. 2, pp. 83-94. https://doi.org/10.2217/pgs-2017-0146
Willrich MAV, Kaleta EJ, Bryant SC, Spears GM, Train LJ, Peterson SE et al. Genetic variation in statin intolerance and a possible protective role for UGT1A1. Pharmacogenomics. 2018 Jan 1;19(2):83-94. https://doi.org/10.2217/pgs-2017-0146
Willrich, Maria Alice V. ; Kaleta, Erin J. ; Bryant, Sandra C. ; Spears, Grant M. ; Train, Laura J. ; Peterson, Sandra E. ; Lennon, Vanda A ; Kopecky, Stephen L. ; Baudhuin, Linnea M. / Genetic variation in statin intolerance and a possible protective role for UGT1A1. In: Pharmacogenomics. 2018 ; Vol. 19, No. 2. pp. 83-94.
@article{acd7e6ddc13842188db2436faa28f138,
title = "Genetic variation in statin intolerance and a possible protective role for UGT1A1",
abstract = "The etiology of statin intolerance is hypothesized to be due to genetic variants that impact statin disposition and clearance. We sought to determine whether genetic variants were associated to statin intolerance. The studied cohort consisted of hyperlipidemic participants (n = 90) clinically diagnosed with statin intolerance by a cardiologist and matched controls without statin intolerance. Creatine kinase activity, lipid profiles and genetic analyses were performed on genes involved in statin metabolism and included UGT1A1 and UGT1A3 sequencing and targeted analyses of CYP3A4∗22, CYP3A5∗3, SLCO1B1∗5 and ∗1b, ABCB1 c.3435C>T, ABCG2 c.421C>A and GATM rs9806699. Although lipids were higher in cases, genetic variant minor allele frequencies were similar between cases and controls, except for UGT1A1∗28, which was less prevalent in cases than controls.",
keywords = "ABC transporters, CYP3A, GATM, genetic variants, myotoxicity, precision medicine, SLC, statin intolerance, statins, transporters, UGT",
author = "Willrich, {Maria Alice V.} and Kaleta, {Erin J.} and Bryant, {Sandra C.} and Spears, {Grant M.} and Train, {Laura J.} and Peterson, {Sandra E.} and Lennon, {Vanda A} and Kopecky, {Stephen L.} and Baudhuin, {Linnea M.}",
year = "2018",
month = "1",
day = "1",
doi = "10.2217/pgs-2017-0146",
language = "English (US)",
volume = "19",
pages = "83--94",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Genetic variation in statin intolerance and a possible protective role for UGT1A1

AU - Willrich, Maria Alice V.

AU - Kaleta, Erin J.

AU - Bryant, Sandra C.

AU - Spears, Grant M.

AU - Train, Laura J.

AU - Peterson, Sandra E.

AU - Lennon, Vanda A

AU - Kopecky, Stephen L.

AU - Baudhuin, Linnea M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The etiology of statin intolerance is hypothesized to be due to genetic variants that impact statin disposition and clearance. We sought to determine whether genetic variants were associated to statin intolerance. The studied cohort consisted of hyperlipidemic participants (n = 90) clinically diagnosed with statin intolerance by a cardiologist and matched controls without statin intolerance. Creatine kinase activity, lipid profiles and genetic analyses were performed on genes involved in statin metabolism and included UGT1A1 and UGT1A3 sequencing and targeted analyses of CYP3A4∗22, CYP3A5∗3, SLCO1B1∗5 and ∗1b, ABCB1 c.3435C>T, ABCG2 c.421C>A and GATM rs9806699. Although lipids were higher in cases, genetic variant minor allele frequencies were similar between cases and controls, except for UGT1A1∗28, which was less prevalent in cases than controls.

AB - The etiology of statin intolerance is hypothesized to be due to genetic variants that impact statin disposition and clearance. We sought to determine whether genetic variants were associated to statin intolerance. The studied cohort consisted of hyperlipidemic participants (n = 90) clinically diagnosed with statin intolerance by a cardiologist and matched controls without statin intolerance. Creatine kinase activity, lipid profiles and genetic analyses were performed on genes involved in statin metabolism and included UGT1A1 and UGT1A3 sequencing and targeted analyses of CYP3A4∗22, CYP3A5∗3, SLCO1B1∗5 and ∗1b, ABCB1 c.3435C>T, ABCG2 c.421C>A and GATM rs9806699. Although lipids were higher in cases, genetic variant minor allele frequencies were similar between cases and controls, except for UGT1A1∗28, which was less prevalent in cases than controls.

KW - ABC transporters

KW - CYP3A

KW - GATM

KW - genetic variants

KW - myotoxicity

KW - precision medicine

KW - SLC

KW - statin intolerance

KW - statins

KW - transporters

KW - UGT

UR - http://www.scopus.com/inward/record.url?scp=85038555823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038555823&partnerID=8YFLogxK

U2 - 10.2217/pgs-2017-0146

DO - 10.2217/pgs-2017-0146

M3 - Article

VL - 19

SP - 83

EP - 94

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 2

ER -